Haisike Pharmaceutical Group Co., Ltd. Announcement on the Completion of the Implementation of the Share Reduction Plan by One of the Shareholders Holding Over 5% as Concerted Parties

Log in to the Sina Finance app to search for 【information disclosure】 to view more evaluation levels

Stock code: 002653 Stock abbreviation: Hisun Pharmaceuticals Announcement No.: 2026-027

Hisun Pharmaceuticals Group Co., Ltd.

Announcement on the completion of a share reduction plan implemented by one of the persons acting in concert with shareholders holding more than 5%

Shareholders Yang Fei, Fan Xiulian, Hao Congmei, and Zheng Wei guarantee that the information disclosed to the Company is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.

The Company and all members of its board of directors guarantee that the contents of this announcement are consistent with the information provided by the information disclosure obligor.

Hisun Pharmaceuticals Group Co., Ltd. (hereinafter referred to as the “Company”) disclosed on February 3, 2026 the “Pre-Disclosure Announcement on the Share Reduction Plan by One of the Persons Acting in Concert with Shareholders Holding More Than 5%” (Announcement No.: 2026-015). Hao Congmei and Yang Fei plan to, within three months after fifteen trading days from the date of disclosure of the announcement, reduce the Company’s shares in total of no more than 10,000,000 shares through block trading or centralized bidding, with the total reduction ratio not exceeding 0.89% of the Company’s total share capital.

Among them, Hao Congmei intends to reduce the Company’s shares by no more than 2,000,000 shares, with the reduction ratio not exceeding 0.18% of the Company’s total share capital; Yang Fei intends to reduce the Company’s shares by no more than 8,000,000 shares, with the reduction ratio not exceeding 0.71% of the Company’s total share capital.

Recently, the Company received the “Notification Letter on the Completion of the Share Reduction Plan” issued by Hao Congmei and Yang Fei. The relevant details are hereby announced as follows:

I. Shareholder share reduction

1. Details of the shares reduced by shareholders

■

2. Shareholding changes before and after this reduction by the reducing party and its persons acting in concert

■■

■

Note: The discrepancy between the above total figures and the sums of the figures for the individual items is due to rounding.

II. Other relevant explanations

1. This share reduction complies with relevant laws, regulations, and regulatory documents, including the “Securities Law of the People’s Republic of China,” the “Interim Measures for the Management of Share Reductions by Shareholders of Listed Companies,” and the “Guidelines on Self-Regulation for Listed Companies of the Shenzhen Stock Exchange No. 18—Share Reductions by Shareholders, Directors, and Senior Management Personnel,” among others.

2. The share reduction matter has been made in accordance with the relevant provisions for pre-disclosure. As of the date of disclosure of this announcement, this share reduction plan has been implemented to completion. The shareholders’ share reduction situation is consistent with the previously pre-disclosed share reduction plan, and the actual number of shares reduced has not exceeded the number of shares planned for reduction.

3. This share reduction will not result in a change in the Company’s controlling right, and will not have an impact on the Company’s governance structure, equity structure, or continuing operations.

III. Documents for reference

The “Notification Letter on the Completion of the Share Reduction Plan” issued by Hao Congmei and Yang Fei.

This is hereby announced.

Board of Directors of Hisun Pharmaceuticals Group Co., Ltd.

April 7, 2026

Huge amounts of information and precise interpretation—available on the Sina Finance app